These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

138 related items for PubMed ID: 1517806

  • 21. In vitro activity of cefdinir (FK482) and ten other antibiotics against gram-positive and gram-negative bacteria isolated from adult and pediatric patients.
    Sultan T, Baltch AL, Smith RP, Ritz W.
    Chemotherapy; 1994; 40(2):80-91. PubMed ID: 8131638
    [Abstract] [Full Text] [Related]

  • 22. Combination cefixime/amoxicillin against penicillin-resistant Streptococcus pneumoniae infection.
    Matsumoto Y.
    Chemotherapy; 1998 Sep; 44 Suppl 1():6-9. PubMed ID: 9797416
    [Abstract] [Full Text] [Related]

  • 23. Comparative activity of garenoxacin and other agents by susceptibility and time-kill testing against Staphylococcus aureus, Streptococcus pyogenes and respiratory pathogens.
    Noviello S, Ianniello F, Leone S, Esposito S.
    J Antimicrob Chemother; 2003 Nov; 52(5):869-72. PubMed ID: 14519672
    [Abstract] [Full Text] [Related]

  • 24. Cefixime. A review of its antibacterial activity. Pharmacokinetic properties and therapeutic potential.
    Brogden RN, Campoli-Richards DM.
    Drugs; 1989 Oct; 38(4):524-50. PubMed ID: 2684593
    [Abstract] [Full Text] [Related]

  • 25. Cefixime in the treatment of respiratory and urinary tract infections.
    Ludwig E.
    Chemotherapy; 1998 Sep; 44 Suppl 1():31-4. PubMed ID: 9797422
    [Abstract] [Full Text] [Related]

  • 26. In vitro activity evaluations of cefdinir (FK482, CI-983, and PD134393). A novel orally administered cephalosporin.
    Briggs BM, Jones RN, Erwin ME, Barrett MS, Johnson DM.
    Diagn Microbiol Infect Dis; 1991 Sep; 14(5):425-34. PubMed ID: 1797457
    [Abstract] [Full Text] [Related]

  • 27. Antibacterial activity of oral antibiotics against community-acquired respiratory pathogens from three European countries.
    Schito GC, Georgopoulos A, Prieto J.
    J Antimicrob Chemother; 2002 Jul; 50 Suppl():7-11. PubMed ID: 12077154
    [Abstract] [Full Text] [Related]

  • 28. [Cefixime in urinary tract infections. (Specific studies and literature review)].
    Naber KG.
    Infection; 1990 Jul; 18 Suppl 3():S132-9. PubMed ID: 2079373
    [Abstract] [Full Text] [Related]

  • 29. [In vitro antibacterial effect of a new oral cephalosporin, cefixime. Results of a multicenter study].
    Soussy CJ, Kitzis MD, Thabaut A, Chanal M, Bure A, Vergnaud M, Reynaud AE, Coulet M, Dabernat H, Muller-Serieys C.
    Pathol Biol (Paris); 1989 Jun; 37(5 Pt 2):528-33. PubMed ID: 2508039
    [Abstract] [Full Text] [Related]

  • 30. Cefixime. A review of its therapeutic efficacy in lower respiratory tract infections.
    Markham A, Brogden RN.
    Drugs; 1995 Jun; 49(6):1007-22. PubMed ID: 7641600
    [Abstract] [Full Text] [Related]

  • 31. [Fundamental and clinical studies on cefixime in pediatrics].
    Iwai N, Shibata M, Mizoguchi F, Nakamura H, Katayama M.
    Jpn J Antibiot; 1986 Apr; 39(4):1087-105. PubMed ID: 3761539
    [Abstract] [Full Text] [Related]

  • 32. Pharmacodynamics of ceftriaxone and cefixime against community-acquired respiratory tract pathogens.
    Owens RC, Tessier P, Nightingale CH, Ambrose PG, Quintiliani R, Nicolau DP.
    Int J Antimicrob Agents; 2001 Jun; 17(6):483-9. PubMed ID: 11397619
    [Abstract] [Full Text] [Related]

  • 33. [Clinical evaluation of cefixime in children].
    Meguro H, Arimasu O, Sohda H, Yoshida J, Togasaki K, Fujii R.
    Jpn J Antibiot; 1986 Apr; 39(4):1007-19. PubMed ID: 3761534
    [Abstract] [Full Text] [Related]

  • 34. Combinations of orally administered beta-lactams to maximize spectrum and activity against drug-resistant respiratory tract pathogens: I. Synergy studies of amoxicillin and cefixime with Streptococcus pneumoniae.
    Jones RN, Johnson DM.
    Diagn Microbiol Infect Dis; 1998 Jun; 31(2):373-6. PubMed ID: 9635912
    [Abstract] [Full Text] [Related]

  • 35. Comparative activity of cefixime and cefaclor in an in vitro model simulating human pharmacokinetics.
    Nies BA.
    Eur J Clin Microbiol Infect Dis; 1989 Jun; 8(6):558-61. PubMed ID: 2504600
    [Abstract] [Full Text] [Related]

  • 36. Cefixime: spectrum of antibacterial activity against 16,016 clinical isolates.
    Barry AL, Jones RN.
    Pediatr Infect Dis J; 1987 Oct; 6(10):954-7. PubMed ID: 3696835
    [Abstract] [Full Text] [Related]

  • 37. In vitro activity of ertapenem against selected respiratory pathogens.
    Marchese A, Gualco L, Schito AM, Debbia EA, Schito GC.
    J Antimicrob Chemother; 2004 Nov; 54(5):944-51. PubMed ID: 15472001
    [Abstract] [Full Text] [Related]

  • 38. Antibacterial profile of flurithromycin, a new macrolide.
    Saverino D, Debbia EA, Pesce A, Lepore AM, Schito GC.
    J Antimicrob Chemother; 1992 Sep; 30(3):261-72. PubMed ID: 1452490
    [Abstract] [Full Text] [Related]

  • 39. Ofloxacin, a new broad-spectrum fluoroquinolone. Results from a Multicenter, National Comparative Activity Surveillance Study. The Ofloxacin Surveillance Group.
    Jones RN, Reller LB, Rosati LA, Erwin ME, Sanchez ML.
    Diagn Microbiol Infect Dis; 1992 Jul; 15(5):425-34. PubMed ID: 1643819
    [Abstract] [Full Text] [Related]

  • 40. In vitro activity of a new cephalosporin ME-1206 compared with other agents.
    Chin NX, Zhang YX, Neu HC.
    Diagn Microbiol Infect Dis; 1991 Jul; 14(5):417-24. PubMed ID: 1797456
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.